Neurocrine BiosciencesFRA:NB3 +0.23%94 Days Inventory is 438.47 as of Mar. 2026, which is 15% below its 10-year median of 513.68. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €163.30 (Fairly Valued). The stock has 6 warning signs investors should review. Among 919 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 92.71% on this metric.
The historical rank and industry rank for Neurocrine Biosciences's Days Inventory or its related term are showing as below:
FRA:NB3'
s Days Inventory Range Over the Past 10 Years
Min: 298.05 Med: 513.68 Max: 818.54
Current: 410.45
During the past 13 years, Neurocrine Biosciences's highest Days Inventory was 818.54. The lowest was 298.05. And the median was 513.68.
FRA:NB3's Days Inventory is ranked worse than 92.71% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs FRA:NB3: 410.45
Neurocrine Biosciences's Days Inventory
declined
from Mar. 2025 (586.98) to Mar. 2026 (438.47).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Neurocrine Biosciences's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.21.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Neurocrine Biosciences's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.08.
Neurocrine Biosciences (FRA:NB3) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Neurocrine Biosciences's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Neurocrine Biosciences's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Neurocrine Biosciences Days Inventory Related Terms
Neurocrine Biosciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, ELAN, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a Days Inventory of 438.47 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Neurocrine Biosciences and its competitors. This is 15% below median its historical median of 513.68. Over the past decade, Neurocrine Biosciences' Days Inventory has ranged from 298.05 to 818.54. According to the industry distribution chart, Neurocrine Biosciences ranks #852 out of 919 companies in the Drug Manufacturers industry, placing it in the top 92.7%.
Is Neurocrine Biosciences' Days Inventory too high?
Neurocrine Biosciences' current Days Inventory of 438.47 is 15% below median its 10-year median of 513.68. Over the past 10 years, this metric has ranged from a low of 298.05 to a high of 818.54. The Drug Manufacturers industry median Days Inventory is 164.48. Neurocrine Biosciences' value of 438.47 is 166.6% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #852 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Days Inventory compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #852 out of 919 companies for Days Inventory. This places Neurocrine Biosciences in the lower half of its industry. The industry median Days Inventory is 164.48. Neurocrine Biosciences' value of 438.47 is 166.6% above this benchmark. Historically, Neurocrine Biosciences' own Days Inventory has ranged from 298.05 to 818.54 over the past decade. While the company's 10-year median is 513.68 vs. the industry median of 164.48, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Days Inventory of 438.47 is 166.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Days Inventory is 438.47, which is 15% below median its own 10-year median of 513.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €163.30, compared to a current price of €153.55 — trading 6% below its estimated fair value. The current Days Inventory is 438.47, which is 15% below median its 10-year median of 513.68 and 166.6% above the Drug Manufacturers industry median of 164.48. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Days Inventory is 438.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €153.55 is trading 6% below its estimated GF Value™ of €163.30.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for FRA:NB3:
Days Inventory: 438.47 (15% below median its 10-year median of 513.68)
GF Value™: €163.30 vs. price of €153.55 (6% below fair value)
Industry Position: 166.6% above the Drug Manufacturers median (#852 of 919)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
